4.40
4.40 (0.93%)
As of Aug 16, 2023
Diffusion Pharmaceuticals Inc. [DFFN]
Source:
Company Overview
Cervomed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. We are currently focused on the development of our lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38α in the neurons of people with neurodegenerative diseases.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | (617) 744-4400 |
| Industry | manufacturing |
| CEO | John Alam, M.D. |
| Website | www.diffusionpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $9.7 |
| Operating Profit | $-18.2 |
| Net Income | $-16.3 |
| Net Cash | $1.2 |
Profit Ratios
| Gross Margin | $9.7 |
| Operating Margin | -187.2 |
| Profit as % of Revenues | -59.8% |
| Profit as % of Assets | -61.4% |
| Profit as % of Stockholder Equity | -41.6% |
Management Effectiveness
| Return on Equity | -41.6% |
| Return on Assets | -37.8% |
| Turnover Ratio | 36.7% |
| EBITA | $-18.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $43.1 |
| Total Liabilities | $3.9 |
| Operating Cash Flow | $-16.5 |
| Investing Cash Flow | $-28.7 |
| Financing Cash Flow | $46.4 |
